The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies

Niraj Shenoy*, Makardhwaj Shrivastava*, Vineeth Sukrithan, Dimitra Papaspyridi, Karine Darbinyan

Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA
Email: *knirajshenoy@gmail.com

Received 21 May 2015; accepted 13 June 2015; published 17 June 2015

Copyright © 2015 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract

The Hypoxia Inducible factor (HIF) pathway is known to be constitutionally active in various cancers and is the dominant pathway in some cancers such as VHL mutant clear cell Renal cell carcinoma. HIF-1α and HIF-2α overexpression is known to be important for tumor cell proliferation, maintenance of stemness and angiogenesis. There has been growing interest in therapeutic strategies targeting the HIF pathway over the last decade. We review in this section the role of hypoxia inducible factor pathway in carcinogenesis, its crosstalk with other pathways and potential cancer therapeutic strategies targeting the HIF pathway, its upstream regulators and downstream signaling.

Keywords

Hypoxia Inducible Factor (HIF), Cancer Therapy

1. Introduction and Brief Overview of the HIF Pathway

Under normoxic conditions, prolyl hydroxylases in the presence of Fe2+ and 2-oxoglutarate (2-OG), hydroxylate the proline residues in the Oxygen Degradation Domain of the α subunit of HIF-α. The hydroxylated HIF-α then binds to VHL and undergoes polyubiquitination and proteasomal degradation. Under hypoxic conditions, the hydroxylase activity is inhibited and HIF-α is stabilized and translocated to the nucleus and binds to hypoxia response elements in the promoter regions to promote the expression of target genes.

*Equal contribution.
#Corresponding author.

tions, the HIF-α proteins are not hydroxylated, leading to stabilization and translocation to the nucleus where they combine with constitutionally expressed HIF-1β to form heterodimers that bind to hypoxia response elements in a wide range of promoters and induce the expression of target genes. The pattern of transcription mediates cellular responses to hypoxia and can up-regulate the expression of multiple genes that contribute to cancer progression through survival, angiogenesis, invasion and metastasis. It is therefore not surprising that there has been growing interest in targeting the HIF pathway as a potential cancer therapeutic strategy.

2. Interaction of the HIF Pathway with Other Pathways Involved in Carcinogenesis

2.1. Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (AKT)/Mammalian Target of Rapamycin (mTOR) Pathway

PI3K/AKT/mTOR pathway is implicated in HIF protein synthesis in certain types of cancers [1]-[4]. Activation of receptor tyrosine kinases (ex-EGFR, VEGFR, HGF, FGFR etc.) by their ligands stimulates mTOR via PI3K/AKT signaling thereby activating the translation of HIF-1α mRNA to protein [4]-[6]. AKT enhances translation of HIF-1α via mTOR dependent and mTOR independent pathways [7]. Inactivating mutations of tumor suppressor PTEN leads to enhanced PI3K levels, thereby augmenting the downstream HIF pathway.

2.2. RAS-RAF-MEK-ERK Pathway

Activating mutations of KRAS occurs in 35% - 40% of colon cancers [8]. Kikuchi et al., in their study on caco2 cell line, demonstrated increased hypoxic induction of HIF-1α probably mediated by PI3K pathway [9]. Kang et al. showed that binding of RAGE (receptor for advanced glycation end products) to KRAS mediated HIF-1α induction thereby promoting pancreatic tumor growth under hypoxic conditions [10]. They further postulated that RAGE production is augmented under hypoxic conditions by NFκB. So under hypoxic conditions NFκB leads to increased hypoxic expression of NFκB which binds to KRAS thereby effecting the downstream signaling via RAF-MEK-ERK and PI3K-AKT leading to increased translation and stabilization of HIF-1α. Role of NFκB in upregulation of HIF-1α via AkT was also shown in a study on prostate cancer cells by Sun et al. [11].

2.3. Tumor Suppressor Genes—VHL and p53

Under normoxic conditions the VHL gene product pVHL, degrades the hydroxylated HIF-1α [12]. Under hypoxic conditions or deficiency of functional VHL tumor suppressor protein, the HIF pathway gets activated, enabling the rapid proliferation of tumor cells [13] [14]. Defective VHL function leading to HIF-1α activation has also been linked to suppression of E-cadherin (homophilic cell adhesion molecule with anti-invasive properties) expression in cancers [15]-[17]. Evans et al. demonstrated increased E-cadherin expression in clear cell renal cell carcinoma cell line by using RNA interference-mediated knockdown of HIF-1α [18].

In contrast to VHL, the interaction between TP53 and HIF is complex, with both shown to affect the other’s functioning [19]. HIF 1α acting via inhibition of MDM2 has been shown to stabilize TP53 and increases its level [20], but Hammond et al. postulated that hypoxia induced TP53 is not coupled to the most common p53 target genes like CBP (CREB-binding protein) and p300 [21].

TP53 itself causes degradation of HIF-1α (self regulatory loop of HIF-1α). Ravi et al. demonstrated the role of PI3K/Akt/Snail signaling as a downstream mediator of action of Bmi1 in promoting EMT [28]. They also demonstrated the role of PI3K/Akt/Snail signaling as a downstream mediator of action of Bmi1 in promoting EMT [28] similar to a previous study by Guo et al. [29].
Bmi has been shown as essential mediator of Twist1-induced EMT [30] and also EMT by suppression of PTEN [31]. Furthermore HIF-1α induces Twist expression under hypoxic conditions [32]. Interestingly, it has been suggested in the recent past that HIF may be a link between coagulation disorders and metastasis via thrombin mediated upregulation of HIF-1α-induction of Twist [33].

Bmi1 is an important critical component of polycomb repressive complex, that mediates stemness and self-renewal [34]-[36], and its elevated expression correlates with advanced stage and unfavourable overall survival [29]. Furthermore, effects of hedgehog signaling in self-renewal of malignant cells have been demonstrated to be mediated via Bmi1 [37]. Along with Twist1, Bmi1 have been shown to downregulate E-cadherin and p16INK4a (an important cell cycle regulator) [30]. Bmi1 may thus be extrapolated as an important downstream mediator involved in various aspects of tumor growth. Blocking HIF-1α (which upregulates production of Bmi1) may mitigate these multiple steps in tumorigenesis, tumor stem cell development, self renewal, invasion and metastasis.

TGF-β pathway has also been implicated in hypoxia mediated EMT in liver [38]. Han et al. demonstrated that the EMT effect of TGF β-1 is mediated through HIF. Overexpression of prolly hydroxylase-2 (which inhibits HIF-1α) almost completely inhibited TGF β-1 induced EMT. Increased SMAD2/SMAD3 level (components of the TGF β pathway) was shown to inhibit prolly hydroxylase leading to accumulation of HIF-1α [39]. Another study has demonstrated this relationship between HIF-1α and TGF-β/Smad2/3 signaling [40].

HIF-1α upregulates Survivin, a member of the “Inhibitor of apoptosis/IAP” family [41] [42]. Inhibition of Survivin has in turn been demonstrated to reduce HIF-1α and TGF-β in a study on salivary adenocarcinoma [43].

2.5. HIF and Sonic Hedgehog Signaling (SHH)

Recent studies have also shown the involvement of Sonic Hedgehog (SHH) signaling as a modulating pathway for the HIF-1α in tumoral migration, proliferation and invasiveness. In their study on Neuroblastoma cells, Chen et al. demonstrated significant up-regulation of HIF-1α level associated with overexpression of SHH components [44]. They also demonstrated reversal of pro-migration and proliferative effects of HIF-1α by disrupting SHH signaling [44]. Similarly an interplay in the SHH signaling and HIF-1α was demonstrated by Onishi et al. in their study on pancreatic cancer [45]. Lei et al. demonstrated role of HIF-1α and SHH signaling in EMT in pancreatic cancer model [46].

2.6. HIF and NOTCH Signaling—Cell Differentiation

Under hypoxic conditions HIF-1α binds to the intracellular domain of Notch and augments the downstream responses of the Notch ICD/ CSL transcription complex [47]. In order to elucidate the correlation between the two pathways Irshad et al. studied the gene signatures in Human glioblastoma gliomaspheres and monolayer cultures [48]. They observed up-regulated mRNA of HIF-1α and its downstream targets-PGK1, VEGF, CA9 and OPN and also the components of Notch signaling namely Notch1, Notch3, Jag1, Dll1, Hes1, Hes6 and Hey1. In the gene cluster analysis they found the best association between PGK1 and OPN with notch signaling. Similarly the Notch subset that was maximally associated with overexpression of hypoxia markers comprised of Notch1/Dll1/Hey1/Hes1/Hes6/Hey1/Hey2 [48].

HIF-1α and Notch signaling interdependence has been implicated in maintaining the cells in undifferentiated state [49]. HIF mediated Increased Dll4-notch-hev2 signaling has also been shown in endothelial progenitor cells suggesting a role of this cross-talk in tumor angiogenesis [50]. Another complexity to this pathway interaction was suggested in a study which demonstrated that the Notch intracellular domain might be sequestering Factor-inhibiting HIF-1(FIH-1) away from HIF-1α thus allowing downstream effects of HIF-1α under hypoxic conditions [51].

2.7. HIF and MITF (Microphthalmia Associated Transcription Factor)

MITF enhances the transcription of HIF-1α. In normal cells under normoxic condition, SUMO binds to MITF and decreases the transcription of HIF-1α but in hypoxia, SUMO is released from MITF, resulting in increased transcription of HIF1α. However, the MITF (E318K) mutant seen in some cases of melanoma is resistant to sumoylation, resulting in increased transcription of HIF1α even under normoxic conditions [52] [53].
2.8. HIF and Chemokines

Chemokine receptor 4 (CXCR4) is a cell surface receptor that has been implicated in mediating invasion and metastasis in many cancers [54]-[56]. Phillips et al. demonstrated dramatic expression of CXCR4 under hypoxic conditions and also by EGFR in non-small cell lung cancer (NSCLC) via HIF-1α dependent transcription [57].

Likewise, Li et al. studied the role of CCR7 and HIF in NSCLC. They demonstrated HIF-1α mediated overexpression of CCR7 gene which, via ERK1/2 pathways enhanced invasion and migration of NSCLC cells under hypoxic conditions [31]. Increased CCR7 expression via HIF-1α has been also shown to mediate invasiveness in breast cancer cells [58].

2.9. HIF and Cellular Metabolism

As noted above, HIF is an important driving force modulating many steps in cancer progression-angiogenesis, invasion and metastasis. Its role in cell survival and proliferation is underlined by its effect on cellular metabolism-the Warburg effect [59] [60]. HIF-1α regulates the transcriptional activation on GLUT-1, GLUT-3, hexokinase gene [61]-[63] and also regulates Lactate dehydrogenase (LDHA) and monocarboxylate transporter 4 (MCT4) [61] [64] and enables the rate of anaerobic glycolysis to be increased several fold in cancer. It enables glycolytic intermediates to be used for synthesis of nucleotides and lipids [65]. HIF-1α also activates pyruvate dehydrogenase kinase 1 (PDK1) thereby shunting away the pyruvate from TCA cycle, an important adaptive response to hypoxia [66] [67]. The role of MYC in modulating these metabolic effects of HIF-1α have been increasingly recognized [68] [69].

2.10. HIF and Epigenetics

A recent study on DNA methylation in RCC revealed that RCC samples were characterized by widespread hypermethylation that preferentially affected gene bodies and enhancer regions. MOTIF analysis of aberrantly hypermethylated regions revealed enrichment for binding sites of HIF1α-HIF1β transcription factors, suggesting possible contributions of dysregulated hypoxia signaling pathways towards epigenetic changes in RCC [70]. Histone deacetylase inhibitors have been shown to repress the transactivation potential of both HIF 1α and HIF 2α [71] (Figure 1).

![Figure 1](image-url)

**Figure 1.** The regulation and interaction of HIF pathway with PI3k-AKT-mTOR, Ras-Raf-Mek-Erk, NFκB, TGF-β, Hedgehog, Notch, Microphthalmia associated transcription factor pathways, p53 and VHL; the fate of HIFα in normoxia and hypoxia.
3. Potential Cancer Therapy Strategies Targeting HIF Pathway, Downstream Signaling and Upstream Regulation

3.1. Simultaneous Inhibition of HIF 1α and HIF 2α

A majority of HIF pathway targeting strategies thus far have focused on the inhibition of HIF 1α—be it indirectly via modulation of upstream regulators [72] or via small molecule inhibitors [73]-[75]. However, there is increasing evidence that HIF 2α plays a prominent role in some tumors and in cancer stem cells. Cancer stem cells are very resistant to radiotherapy and chemotherapy and are thought to be responsible for relapse. HIF 2α inhibition has also been shown to promote p53 activity, increase apoptosis and enhance radiation response [76]. Targeting HIF 2α with small molecule inhibitors [77] is therefore a tempting strategy. Given that HIF 1α and HIF 2α have different sets of transcriptional targets and different regulators, [72] simultaneous inhibition of both with small molecule inhibitors could reveal the complete potential of HIF pathway inhibition in cancer therapy.

3.2. LDH-A Inhibition

Lactate dehydrogenase isoenzyme A is one of the enzymes directly upregulated by the HIF pathway. It converts pyruvate to lactate, utilizing NADH. The upregulation of LDHA enables tumors to increase the rate of anaerobic glycolysis several fold and is by far the main source of ATP in tumors, especially in the hypoxic areas. The lactate produced is shunted out of tumor cells and used as a source of energy via gluconeogenesis in the surrounding stroma/microenvironment. The LDH isoenzyme present in RBCs, heart and brain is LDHB and a selective LDHA inhibitor would not affect these organs. The LDH isoform is found in skeletal muscle and liver. In fact, hereditary LDHA deficiency is reasonably well tolerated with the only manifestation being a mild myopathy and myoglobinuria during strenuous activity. Inhibiting LDHA has been shown to result in induction of apoptosis in cancer cells and reduced proliferation in-vitro. It has also been shown to increase the redox-sensitive anti-cancer drug EO9 induced DNA damage, with no additive effect on the normal cells [78]. LDHA is therefore considered a potentially safe and promising target in cancer therapy and clinical trials are underway to determine the safety and efficacy of its inhibition in cancer [79].

Monocarboxylate transporters (MCTs) involved in the transport of lactate and protons into and out of cells are also being considered as potential targets. MCT1 and MCT4 are overexpressed in cancers. Although MCT inhibition has shown good antitumor activity in-vitro, it could potentially cause a lot more side effects compared to LDHA inhibition, given its ubiquitous expression and its role in utilizing lactate as a substrate for gluconeogenesis and maintenance of intracellular pH.

3.3. Vitamin C

Low cellular ascorbic acid has been shown to be associated with increased HIF activity and aggressive phenotype of endometrial cancer and ascorbate supplementation has been shown to suppress HIF activation by prolyl hydroxylation [80] [81]. High dose vitamin C has been studied as a treatment for cancer patients since 1970s. Laboratory and animal studies have shown that high dose vitamin C reduces the proliferation of colon, liver, pancreas, prostate, malignant mesothelioma cancer cells and blocks tumor growth. It has also been shown that combining vitamin C with chemotherapy may be more effective than chemotherapy alone in pancreatic cancer and ovarian cancer. Clinical studies with high dose vitamin C has shown that it results in a better quality of life and fewer side effects in cancer patients on adjuvant chemotherapy and radiation. Another study showed that patients with advanced pancreatic cancer who received a combination of chemotherapy and vitamin C had stable disease for a few months. That effect was not replicated in studies on some other cancers and more clinical trials with vitamin C with chemotherapy are underway with a recent resurgence of interest in its potential as a therapeutic agent (http://www.cancer.gov/cancertopics/pdq/cam/highdosevitaminC/patient/page2). Recently, it was shown that HIF increases the sensitivity of the cancer cells to vitamin C induced toxicity. HIF increases the intracellular uptake of oxidized vitamin C through its transcriptional target Glut 1 and reduced Vitamin C though sodium dependent Vc transporters (SVCTs). The resulting high levels of vitamin C induces oxidative stress, DNA damage and depletes ATP reserves leading to cell death [82]. Interestingly, the HIF pathway has been shown to have a dominant role in pancreatic cancer, which has shown promising response to high dose vitamin C therapy in clinical trials [83]. Put together, these studies suggest that high dose vitamin C therapy may be most effective in cancers with a dominant HIF pathway. In fact, there are case reports of benefit of vitamin C...
therapy in renal cancer and bladder cancer, which are known to have dominant HIF pathway [84]. Determining the HIF pathway signal transduction activity in tumors and utilizing high dose vitamin C in addition to chemotherapy in a randomized controlled trial in a cohort of cancer patients with high HIF tumor activity, would be a very interesting study. Considering the fact that high dose vitamin C is well tolerated and has negligible side effects in patients with preserved renal function, it is not surprising that surveys of practitioners in United States in recent years have shown that high dose Vitamin C is frequently given to cancer patients.

3.4. Targeting Upstream Regulators of the HIF Pathway

Some chemotherapy agents inhibit upstream regulators of the HIF pathway and a part of their anticancer activity can be attributed to reduction in transcription of the HIF target genes.

Camptothecins like Topotecan and Irinotecan are DNA Topoisomerase 1 (TOP-1) inhibitors. TOP-1 inhibition leads to HIF-1α down-regulation due to reduced translation [85]. Mitomycin C, another DNA damage inducing agent, is also known to reduce HIF 1α translation and reduce HIF 1α protein levels [86]. Bortezomib is a proteasome inhibitor that inhibits the degradation of many intracellular proteins including ubiquinated HIF 1α. However, the accumulated HIF-1α is inactive because of simultaneous upregulation of FIH, which inhibits the interaction of p300 with HIF 1α [87]. Histone deacetylase inhibitors repress the transactivation potential of both HIF 1α and HIF 2α [71]. PI3K/AKT/mTOR pathway inhibitors block the mTOR dependent kinase cascade required for HIF 1α mRNA translation, thereby reducing HIF 1α levels [88] [89].

3.5. Inhibiting the HIF1α-p300 Interaction

Inhibiting the interaction between HIF1α and its transcriptional coactivators would be another approach to inhibit the downstream effects of a dysregulated HIF pathway [90]-[92].

4. Conclusion

The HIF pathway mediates essential features of cancer growth and survival, is constitutionally active in many cancers, and is the central driver pathway in some cancers like clear cell renal cell carcinoma. It interacts with various oncogenic pathways and understanding this complex interaction has helped in developing novel potential therapeutic strategies. A highly active HIF pathway is known to make cancers resistant to chemotherapy and radiotherapy and inhibiting the pathway could therefore potentiate the effect of these treatment modalities. Clinical trials with small molecule inhibitors of HIF α, vitamin C, LDHA inhibitors and regulators of HIF pathway are underway.

References


N. Shenoy et al.


[45] Onishi, H., Morisaki, T., Nakao, F., Odate, S., Morisaki, T. and Katano, M. (2013) Protein-Bound Polysaccharide Decreases Invasiveness and Proliferation in Pancreatic Cancer by Inhibition of Hedgehog Signaling and HIF-1Alpha...


Busca, R., Berra, E., Gaggioli, C., Khaled, M., Bille, K., Marchetti, B., et al. (2005) Hypoxia-Inducible Factor 1Alpha Is a New Target of Microphthalmia-Associated Transcription Factor (MITF) in Melanoma Cells. The Journal of Cell Biology, 170, 49-59. http://dx.doi.org/10.1083/jcb.200501067


Factor-1Alpha Reduces Tumorigenicity of Pancreatic Cancer Cells through the Suppression of Glucose Metabolism.  
*The American Journal of Pathology, 162*, 1283-1291.  
[http://dx.doi.org/10.1016/S0002-9440(10)65924-7](http://dx.doi.org/10.1016/S0002-9440(10)65924-7)


*Cancer Research, 64*, 1475-1482.  
[http://dx.doi.org/10.1158/0008-5472.CAN-03-3139](http://dx.doi.org/10.1158/0008-5472.CAN-03-3139)

*PLoS ONE, 5*, e10522.  
[http://dx.doi.org/10.1371/journal.pone.0010522](http://dx.doi.org/10.1371/journal.pone.0010522)

*Blood, 111*, 3131-3136.  
[http://dx.doi.org/10.1182/blood-2007-11-120576](http://dx.doi.org/10.1182/blood-2007-11-120576)

*Nature Medicine, 12*, 122-127.  
[http://dx.doi.org/10.1038/nm1337](http://dx.doi.org/10.1038/nm1337)

*Molecular Cancer Therapeutics, 2*, 1093-1103.

*European Journal of Medicinal Chemistry, 94*, 509-516.  
[http://dx.doi.org/10.1016/j.ejmech.2014.06.006](http://dx.doi.org/10.1016/j.ejmech.2014.06.006)

*PLoS ONE, 8*, e62014.  
[http://dx.doi.org/10.1371/journal.pone.0062014](http://dx.doi.org/10.1371/journal.pone.0062014)

[http://dx.doi.org/10.1074/jbc.M109.009498](http://dx.doi.org/10.1074/jbc.M109.009498)